• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0
  • HEK293 expressed
  • Endotoxin-free
  • Animal-component free

HumanKine® recombinant human IL-34 protein

Activity

0.45-4.5 ng/mL in MCP-1 ELISA, 2-12 ng/mL in PBMCs Proliferation

Species Reactivity

human

Purity

>95%

Cat No : HZ-1316

Print datasheet

Synonyms

IL34, Interleukin-34, C16orf77, MGC34647

Validation Data Gallery

  • Purity of recombinant human IL-34 was determined by SDS- polyacrylamide gel electrophoresis. The protein was resolved in an SDS- polyacrylamide gel in reducing and non-reducing conditions and stained using Coomassie blue

    Purity of recombinant human IL-34 was determined by SDS- polyacrylamide gel electrophoresis. The protein was resolved in an SDS- polyacrylamide gel in reducing and non-reducing conditions and stained using Coomassie blue

  • Recombinant IL-34 (HZ-1316) stimulates dose-dependent proliferation of PBMCs. Cell number was quantitatively assessed by PrestoBlue® Cell Viability Reagent. PBMCs were treated with increasing concentrations of IL-34 for 6 days. The EC50 was determined using a 4-parameter non-linear regression model. The EC50 range is 2-12 ng/mL.

    Recombinant IL-34 (HZ-1316) stimulates dose-dependent proliferation of PBMCs. Cell number was quantitatively assessed by PrestoBlue® Cell Viability Reagent. PBMCs were treated with increasing concentrations of IL-34 for 6 days. The EC50 was determined using a 4-parameter non-linear regression model. The EC50 range is 2-12 ng/mL.

  • Proteintech IL-34 (HZ-1316) demonstrates a 2-fold decrease in EC50 and equivalent fold induction compared to leading competitors. Recombinant IL-34 stimulates dose-dependent proliferation of PBMCs. Cell number was quantitatively assessed by PrestoBlue® Cell Viability Reagent. PBMCs were treated with increasing concentrations of IL-34 for 6 days. The EC50 was determined using a 4-parameter non-linear regression model. The EC50 range is 2-12 ng/mL.

    Proteintech IL-34 (HZ-1316) demonstrates a 2-fold decrease in EC50 and equivalent fold induction compared to leading competitors. Recombinant IL-34 stimulates dose-dependent proliferation of PBMCs. Cell number was quantitatively assessed by PrestoBlue® Cell Viability Reagent. PBMCs were treated with increasing concentrations of IL-34 for 6 days. The EC50 was determined using a 4-parameter non-linear regression model. The EC50 range is 2-12 ng/mL.

  • Human PBMC cells were seeded at a density of 100,000 cells per well in a non-tissue culture treated ​96-well plate. Cells were cultured in RPMI1640 + 10% FBS treated 100 ng/mL of Proteintech recombinant IL-34 (HZ-1316) for 6 days.

    Human PBMC cells were seeded at a density of 100,000 cells per well in a non-tissue culture treated ​96-well plate. Cells were cultured in RPMI1640 + 10% FBS treated 100 ng/mL of Proteintech recombinant IL-34 (HZ-1316) for 6 days.

  • Recombinant human IL-34 induces dose-dependent release of MCP-1 in human peripheral blood mononuclear cells (PBMCs). PBMCs were treated with increasing concentration of IL-34 for 48 hours before supernatant collection. The supernatant was tested for MCP-1 via ELISA kit. The EC50 was determined using a 4-parameter non-linear regression model. Activity determination was conducted in triplicate on a validated bioassay. The EC50 range is 0.45-4.5 ng/mL.

    Recombinant human IL-34 induces dose-dependent release of MCP-1 in human peripheral blood mononuclear cells (PBMCs). PBMCs were treated with increasing concentration of IL-34 for 48 hours before supernatant collection. The supernatant was tested for MCP-1 via ELISA kit. The EC50 was determined using a 4-parameter non-linear regression model. Activity determination was conducted in triplicate on a validated bioassay. The EC50 range is 0.45-4.5 ng/mL.

  • 1 million THP-1 cells were seeded in a 24-well plate with serum free RPMI 1640 medium overnight. ​ Cells were treated with indicated amounts of IL-34 (HZ-1316) for 5 min before lysis with RIPA buffer. ​ Phosphorylation ERK 1/2 (PTG #28733-1-AP) and total ERK 1/2 (PTG #11257-1-AP) antibodies were​ used to detect IL-34 induced ERK1/2 phosphorylation.

    1 million THP-1 cells were seeded in a 24-well plate with serum free RPMI 1640 medium overnight. ​ Cells were treated with indicated amounts of IL-34 (HZ-1316) for 5 min before lysis with RIPA buffer. ​ Phosphorylation ERK 1/2 (PTG #28733-1-AP) and total ERK 1/2 (PTG #11257-1-AP) antibodies were​ used to detect IL-34 induced ERK1/2 phosphorylation.

Technical Specifications

GeneID 146433
Species Human
Expression HEK293
Activity 0.45-4.5 ng/mL in MCP-1 ELISA, 2-12 ng/mL in PBMCs Proliferation
Purity >95%
Endotoxin<1 EU/µg
Accession NumberQ6ZMJ4
Molecular Mass 38 kDa reduced, 36 and 68 kDa non-reduced, homodimer, glycosylated
Formulation 1 x PBS, See Certificate of Analysis for details
Species Reactivity human

Stability and Reconstitution

Stability and StorageProduct FormTemperature ConditionsStorage Time
(From Date of Receipt)
Lyophilized-20°C to -80°CUntil Expiry Date
LyophilizedRoom Temperature2 weeks
Reconstituted as per CofA-20°C to -80°C6 months
Reconstituted as per CofA4°C1 week
Avoid repeated freeze-thaw cycles.
Reconstitution Briefly centrifuge the vial before opening. It is recommended to reconstitute the protein to 0.2 mg/mL in sterile 1x PBS pH 7.4 + 0.1% HSA. Gently swirl or tap vial to mix.

Background

IL-34 is a 6-α-helix, proinflammatory cytokine that serves as a ligand for colony-stimulating factor-1 receptor (CSF1R). It is expressed most abundantly by spleen cells. It primarily stimulates human peripheral blood monocyte proliferation and macrophage colony formation. It is also required for Langerhans cell and microglia development. IL-34 has been shown to play a protective role in cancer and Alzheimer’s disease, but it can promote the progression of several autoimmune, inflammatory, and metabolic diseases. As such IL-34 could be used as a biomarker to mark the progression of these diseases (PMID: 22579672, 27577879, 31940023).

Synonyms

IL34, Interleukin-34, C16orf77, MGC34647

Publications

SpeciesTitle
human

Cell Metab

Microglial lipid droplet accumulation in tauopathy brain is regulated by neuronal AMPK

Authors - Yajuan Li
View Article

Immunity

Human microglia maturation is underpinned by specific gene regulatory networks

Authors - Claudia Z Han
View Article